Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) EBIT (2021 - 2025)

Prime Medicine (PRME) has disclosed EBIT for 5 consecutive years, with -$48.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 9.92% year-over-year to -$48.6 million, compared with a TTM value of -$208.4 million through Dec 2025, down 2.91%, and an annual FY2025 reading of -$208.4 million, down 2.91% over the prior year.
  • EBIT was -$48.6 million for Q4 2025 at Prime Medicine, up from -$54.0 million in the prior quarter.
  • Across five years, EBIT topped out at -$10.4 million in Q3 2021 and bottomed at -$68.0 million in Q4 2023.
  • Average EBIT over 5 years is -$44.7 million, with a median of -$48.5 million recorded in 2024.
  • Peak annual rise in EBIT hit 37.13% in 2022, while the deepest fall reached 203.59% in 2022.
  • Year by year, EBIT stood at -$61.5 million in 2021, then soared by 37.13% to -$38.7 million in 2022, then crashed by 75.89% to -$68.0 million in 2023, then surged by 35.01% to -$44.2 million in 2024, then dropped by 9.92% to -$48.6 million in 2025.
  • Business Quant data shows EBIT for PRME at -$48.6 million in Q4 2025, -$54.0 million in Q3 2025, and -$53.4 million in Q2 2025.